Tandem Diabetes Care (TNDM) provided an update on the March 2024 recall of its Apple (AAPL) iOS t:connect mobile app in the United States relating to an issue that can cause rapid depletion of a user’s t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to experience following the release of version 2.7.1 of the app in March. Notices were emailed to impacted customers on August 9, 2024 with updated information and recommendations for helping avoid pump battery depletion. Tandem plans to release a new version of the app to address the remaining issues and will notify all users by email and app push notifications following its release. Under-delivery of insulin because of a pump shutdown can result in hyperglycemia or diabetic ketoacidosis, which can be a life-threatening condition due to high blood sugar and lack of insulin. There have been 107 confirmed adverse events with this recall. Adverse events are defined as a confirmed high blood sugar and/or an event requiring medical intervention. Two hospitalizations and no deaths have been reported. Tandem strongly recommends anyone using the Apple iOS t:connect Mobile App with a t:slim X2 insulin pump to do the following: Continue using your Tandem pump and t:connect mobile app as described in the User Guide; and if a low battery alert is received, Tandem strongly recommends charging the device as soon as possible.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Disney downgraded, Arm upgraded: Wall Street’s top analyst calls
- Tandem Diabetes initiated with a Buy at Canaccord
- Stifel sees ‘unexpected diabetes tech marriage’ as negative for DexCom, others
- 3 Best Stocks to Buy Now, 8/5/2024, According to Top Analysts
- Tandem Diabetes price target raised to $58 from $55 at Barclays